- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | 1 | Investing.com Deutsch | ||
| Di | Hemab presents phase 2 data for sutacimig, plans phase 3 trial | 1 | Investing.com | ||
| Di | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| Mo | Hemab Advances Bleeding Disorder Pipeline | 3 | Benzinga.com | ||
| Mo | Hemab Therapeutics stock price target raised to $52 by H.C. Wainwright on trial data | 1 | Investing.com | ||
| So | Hemab Therapeutics, Inc.: Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 10.07. | Gubra A/S: Gubra collaboration partner Hemab to present preclinical results for HMB-003, a potential treatment for multiple bleeding disorders, at the ISTH 2026 Congress | 257 | GlobeNewswire (Europe) | Copenhagen, July 10, 2026: Gubra's collaboration partner Hemab will present preclinical results from the HMB-003 program on July 11, 2026, at the ISTH Congress in Paris.
The preclinical data show that... ► Artikel lesen | |
| 26.06. | Hemab Therapeutics: Positive Studiendaten und Pipeline-Erweiterung treiben Aktie an | - | Investing.com Deutsch | ||
| HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.06. | Hemab announces clinical updates across bleeding disorder pipeline | 2 | Investing.com | ||
| 26.06. | Hemab Therapeutics, Inc.: Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 17.06. | H.C. Wainwright initiates Hemab Therapeutics stock coverage with buy rating | 3 | Investing.com | ||
| 26.05. | Wedbush initiates Hemab Therapeutics stock with outperform rating | 1 | Investing.com | ||
| 26.05. | Jefferies stuft Hemab Therapeutics mit "Buy" ein - Hohes Potenzial bei seltenen Blutgerinnungsstörungen | 1 | Investing.com Deutsch | ||
| 26.05. | Jefferies initiates Hemab Therapeutics stock with buy rating on rare bleeding disorder potential | 1 | Investing.com | ||
| 26.05. | Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential | 2 | Investing.com | ||
| 26.05. | Goldman Sachs stuft Hemab Therapeutics mit "Buy" ein - Potenzial durch Medikament für seltene Krankheiten | 1 | Investing.com Deutsch | ||
| 21.05. | Hemab Therapeutics Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 21.05. | Hemab Therapeutics Holdings, Inc. GAAP EPS of -$23.98 | 1 | Seeking Alpha | ||
| 21.05. | Hemab Therapeutics, Inc.: Hemab Therapeutics Reports First Quarter 2026 Financial Results | 241 | GlobeNewswire (Europe) | Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE... ► Artikel lesen | |
| 21.05. | Hemab Therapeutics Holdings, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,007 | -3,36 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INFLARX | 1,603 | -3,72 % | ACHTUNG bei InflaRx NV: Der Kurs nähert sich einer gefährlichen Marke - Das sollten Sie jetzt wissen | ||
| INTELLIA THERAPEUTICS | 9,990 | -3,57 % | Wolfe Research stuft Intellia Aktie wegen Bewertungsbedenken herab | ||
| IBIO | 1,301 | +9,79 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| IMMUNITYBIO | 6,670 | +2,46 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,520 | +3,59 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,552 | +0,23 % | MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D | Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE... ► Artikel lesen | |
| IMMUNIC | 13,085 | -0,42 % | IMMUNIC, INC. - 8-K, Current Report | ||
| IOVANCE BIOTHERAPEUTICS | 4,345 | +6,76 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,100 | -3,23 % | Moleculin Biotech, Inc.: Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment | Access the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive... ► Artikel lesen | |
| GENPREX | 7,670 | -6,46 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenUS3724463027 Genprex Inc. 15.07.2026 US3724464017 Genprex Inc. 16.07.2026 Tausch 22:1 ► Artikel lesen | |
| MACROGENICS | 3,640 | +0,55 % | MacroGenics Completes $122.5 Million Sale Of GMP Manufacturing Operations To Bora Pharmaceuticals | ||
| MESOBLAST | 1,528 | -7,79 % | Wenn die großen Pharmakonzerne Milliarden in Krebs investieren - entsteht der nächste Zelltherapie-Boom ganz woanders? | ||
| KARYOPHARM | 8,200 | -0,61 % | Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | - Completed Enrollment of Phase 3 XPORT-EC-042 Trial in Endometrial Cancer; Topline Data Expected Mid-2026 -
- Phase 3 SENTRY Results Selected for Late-Breaking... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,274 | -2,14 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
HEMAB THERAPEUTICS HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +10,27 % bei einem Aktienkurs von 49,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMAB THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.